Mark C. Gillies
Elite in Age-Related Macular Degeneration (ARMD)

Mark C. Gillies

8 Macquarie Street, 
Sydney, NSW, AU 
Elite in Age-Related Macular Degeneration (ARMD)
8 Macquarie Street, 
Sydney, NSW, AU 
OverviewLocationsClinical Research

Overview

Mark Gillies practices in Sydney, Australia. Mr. Gillies is rated as an Elite expert by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Macular Edema (DME), Cataract Removal, and Vitrectomy.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 146 articles and participated in 2 clinical trials in the study of Age-Related Macular Degeneration (ARMD).

Gender
Male

Locations

8 Macquarie Street, Sydney, NSW 2000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 09, 2025
Intervention Type: Drug
Study Drug: EXN407
Study Phase: Phase 1/Phase 2
A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema
A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Procedure, Drug
Study Drug: Aflibercept
Study Phase: Phase 4
Pilot Study of Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
Pilot Study of Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
Enrollment Status: Completed
Publish Date: February 07, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

259 Total Publications

Dysregulated Proline Metabolism Contributes to Subretinal Fibrosis in Neovascular AMD: Therapeutic Potential of Prolyl-4-Hydroxylase Inhibition.
Dysregulated Proline Metabolism Contributes to Subretinal Fibrosis in Neovascular AMD: Therapeutic Potential of Prolyl-4-Hydroxylase Inhibition.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gillies's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile